{"id":837956,"date":"2025-04-16T08:11:47","date_gmt":"2025-04-16T12:11:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/"},"modified":"2025-04-16T08:11:47","modified_gmt":"2025-04-16T12:11:47","slug":"evolus-announces-commercial-launch-of-evolysse","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/","title":{"rendered":"Evolus Announces Commercial Launch of Evolysse\u2122"},"content":{"rendered":"

<\/p>\n

Evolus Announces Commercial Launch of Evolysse\u2122<\/b><\/p>\n

NEWPORT BEACH, Calif.–(BUSINESS WIRE<\/a>)–Evolus, Inc.<\/a> (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse\u2122 Form and Evolysse\u2122 Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse\u2122 collection, scheduled for Friday, April 18th.\n<\/p>\n

\nTo support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables providers to explore the performance and versatility of Evolysse\u2122 injectable HA gels for the correction of dynamic facial wrinkles and folds, such as nasolabial folds, which will accelerate comfort, confidence, and integration of the products into clinical practice.\n<\/p>\n

\nThe Evolysse\u2122 collection marks the company\u2019s second commercial aesthetics product, following the successful launch of Jeuveau\u00ae<\/sup> in 2019. Since its launch, Jeuveau\u00ae<\/sup> has become the fastest-growing neurotoxin in the U.S. for four consecutive years and has now captured over 14% of the U.S. market and penetrated over 50% of aesthetic clinics. With over 15,000 purchasing accounts, Evolysse\u2122 will launch into an established customer base who will gain access to Evolysse\u2122 Form and Evolysse\u2122 Smooth, helping to drive immediate and impactful momentum in the U.S. injectable HA market.\n<\/p>\n

\n\u201cWith the introduction of Evolysse\u2122, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade,\u201d said David Moatazedi, President and Chief Executive Officer of Evolus. \u201cThis is more than a product launch, it is the introduction of differentiated injectable HA gels that are grounded in clinical science and designed to meet the evolving needs of consumers seeking natural-looking results. By pairing this innovative Cold-X\u2122 technology with the commercial strength we\u2019ve built with Jeuveau\u00ae<\/sup>, we are well-positioned to expand our leadership with a differentiated injectable portfolio.\u201d\n<\/p>\n

\nDr. John Fezza, MD, an award-winning oculofacial plastic surgeon, commented, \u201cWith over 30 years of experience in the aesthetics industry, I\u2019m excited to integrate Evolysse\u2122 into my practice. These products represent the next generation of injectable HA gels, scientifically driven, delivering natural-looking results, and backed by a strong safety profile. Evolysse\u2122 provides a new level of confidence when treating patients who are concerned about looking overdone or unnatural. It\u2019s exactly what my patients have been asking for.\u201d\n<\/p>\n

\nRepresenting the first breakthrough in HA technology in over a decade, Evolysse\u2122 utilizes innovative Cold-X\u2122 technology by Symatese which is designed to better preserve the natural structure of the HA molecule for long-lasting, natural-looking results. Evolysse\u2122 Form and Evolysse\u2122 Smooth address moderate to severe dynamic facial wrinkles and facial folds that may develop over time for many reasons, including the natural aging process or following weight loss. In a head-to-head clinical study against Restylane\u00ae<\/sup>-L, both Evolysse\u2122 Form and Evolysse\u2122 Smooth met the 6-month primary endpoint of non-inferiority1<\/sup>, with the confidence intervals and corresponding p-values (<0.001) demonstrating statistical superiority1<\/sup>.\n<\/p>\n

\nAdditionally, Evolysse\u2122 Form demonstrated statistically significant differences2<\/sup> compared to Restylane\u00ae<\/sup>-L at all measured timepoints throughout the 12-month study period. Evolysse\u2122 Smooth showed statistically significant differences2<\/sup> at 6 and 9 months, despite 20% more Restylane\u00ae<\/sup>-L being used3<\/sup>. In the head-to-head clinical study versus Restylane\u00ae<\/sup>-L, the safety profile of Evolysse\u2122 Form and Evolysse\u2122 Smooth was similar to the control.\n<\/p>\n

About Evolus, Inc.<\/b><\/p>\n

\nEvolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau\u00ae<\/sup> (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse\u2122, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com<\/a>, and follow us on LinkedIn<\/a>, X<\/a>, Instagram<\/a> or Facebook<\/a>.\n<\/p>\n

1<\/sup> Based on the primary endpoint analysis for Evolysse\u2122 Form (95% CI [-0.500, -0.032]) and Evolysse\u2122 Smooth (95% CI [-0.416, -0.019])\n<\/p>\n

2<\/sup> Based on Wrinkle Severity Rating Scale (WSRS) Live Investigator Assessments (p < 0.05)\n<\/p>\n

3<\/sup> In the clinical study, the mean injection volume for optimal correction was 1.0 mL for Evolysse\u2122 Smooth versus 1.2 mL for Restylane\u00ae<\/sup>-L\n<\/p>\n

\nJeuveau\u00ae<\/sup> and Nuceiva\u00ae <\/sup>are registered trademarks and Evolysse\u2122 is a trademark of Evolus, Inc.
\n
Cold-X\u2122 is a trademark of Symatese Group S.A.S.
\n
Restylane\u00ae<\/sup> is a trademark of Galderma S.A.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250416017875\/en\/<\/a><\/span><\/p>\n

Evolus Contacts:
\n<\/b>
Investors:
\n<\/span>
Nareg Sagherian
\n
Vice President, Head of Global Investor Relations and Corporate Communications
\n
Tel: 248-202-9267
\n
Email: ir@evolus.com
\n<\/a><\/p>\n

Media<\/span>:
\n
Email: media@evolus.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Luxury Women Men Biotechnology Health Cosmetics Consumer Pharmaceutical Retail<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Evolus Announces Commercial Launch of Evolysse\u2122 NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse\u2122 Form and Evolysse\u2122 Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse\u2122 collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables … <\/p>\n

Continue reading “Evolus Announces Commercial Launch of Evolysse\u2122”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEvolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Evolus Announces Commercial Launch of Evolysse\u2122 NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse\u2122 Form and Evolysse\u2122 Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse\u2122 collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables … Continue reading "Evolus Announces Commercial Launch of Evolysse\u2122"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T12:11:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evolus Announces Commercial Launch of Evolysse\u2122\",\"datePublished\":\"2025-04-16T12:11:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/\"},\"wordCount\":814,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/\",\"name\":\"Evolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-04-16T12:11:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-announces-commercial-launch-of-evolysse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evolus Announces Commercial Launch of Evolysse\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/","og_locale":"en_US","og_type":"article","og_title":"Evolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk","og_description":"Evolus Announces Commercial Launch of Evolysse\u2122 NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse\u2122 Form and Evolysse\u2122 Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse\u2122 collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables … Continue reading \"Evolus Announces Commercial Launch of Evolysse\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-16T12:11:47+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evolus Announces Commercial Launch of Evolysse\u2122","datePublished":"2025-04-16T12:11:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/"},"wordCount":814,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/","name":"Evolus Announces Commercial Launch of Evolysse\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-04-16T12:11:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250416017875r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-announces-commercial-launch-of-evolysse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evolus Announces Commercial Launch of Evolysse\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}